STOCK TITAN

Insider buy: QuidelOrtho (QDEL) CEO-linked trust adds 10,540 shares

Filing Impact
(High)
Filing Sentiment
(Positive)
Form Type
4

Rhea-AI Filing Summary

QuidelOrtho Corp President and CEO Brian J. Blaser reported an indirect open-market purchase of common stock through a trust associated with him. On February 13, 2026, the trust bought 10,540 shares at a weighted average price of $23.5921 per share, within a range of $23.4200 to $23.9400.

After this transaction, the trust held 40,073 shares of QuidelOrtho common stock indirectly for Blaser, while he also held 25,142 shares directly. The filing notes that detailed trade-by-trade pricing is available upon request from the reporting person.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Blaser Brian J.

(Last) (First) (Middle)
9975 SUMMERS RIDGE ROAD

(Street)
SAN DIEGO CA 92121

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
QuidelOrtho Corp [ QDEL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
02/13/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/13/2026 P 10,540 A $23.5921(1) 40,073 I By Trust
Common Stock 25,142 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The weighted average purchase price of these transactions was $23.5921 per share, with a range of $23.4200 to $23.9400 per share. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares purchased at each separate price.
Remarks:
/s/ Jennifer Ahn, attorney-in-fact for Brian J. Blaser 02/13/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did QuidelOrtho (QDEL) report for Brian J. Blaser?

QuidelOrtho reported that a trust associated with President and CEO Brian J. Blaser bought 10,540 shares of common stock. The open-market purchase occurred on February 13, 2026 at a weighted average price of $23.5921 per share.

At what price did the QuidelOrtho (QDEL) CEO-linked trust buy shares?

The trust associated with QuidelOrtho’s CEO bought shares at a weighted average of $23.5921 per share. Individual trade prices ranged from $23.4200 to $23.9400, and full trade-by-trade details are available from the reporting person upon request.

How many QuidelOrtho (QDEL) shares does the CEO hold after this Form 4?

After the reported transactions, Brian J. Blaser indirectly held 40,073 QuidelOrtho shares through a trust and directly held 25,142 shares. These figures reflect his beneficial ownership immediately following the February 13, 2026 purchase.

Was the QuidelOrtho (QDEL) CEO’s February 13, 2026 transaction a buy or sell?

The February 13, 2026 transaction reported for QuidelOrtho’s CEO was a buy. A trust associated with Brian J. Blaser executed an open-market purchase of 10,540 shares of QuidelOrtho common stock, coded as a purchase transaction on the Form 4.

How is the QuidelOrtho (QDEL) CEO’s ownership structured in this Form 4?

Brian J. Blaser’s ownership in QuidelOrtho is reported as both indirect and direct. A trust associated with him holds 40,073 shares indirectly, while he also holds 25,142 shares directly, as shown in the beneficial ownership columns of the Form 4.
Quidel

NASDAQ:QDEL

QDEL Rankings

QDEL Latest News

QDEL Latest SEC Filings

QDEL Stock Data

1.96B
66.77M
0.92%
117.99%
11.25%
Medical Devices
In Vitro & in Vivo Diagnostic Substances
Link
United States
SAN DIEGO